FDA Ends Shortage of Eli Lilly’s Weight-Loss Drug, Restricts Copycat Versions

The FDA has ruled that Eli Lilly's tirzepatide supply meets demand, requiring compounding pharmacies to phase out unbranded alternatives within 60 to 90 days.